Ibrutinib Deacryloylpiperidine CAS 330786-24-8 Maʻemaʻe >99.0% (HPLC)

ʻO ka wehewehe pōkole:

Inoa Kemika: Ibrutinib Deacryloylpiperidine

CAS: 330786-24-8

Maʻemaʻe: >99.0% (HPLC)

ʻIke: Keʻokeʻo-keʻokeʻo a i ka pauka Khaki

Kūwaena o Ibrutinib (CAS: 936563-96-1)

Hoʻokaʻaʻike: Kauka Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

E hoʻouna i ka leka uila iā mākou

Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Ibrutinib pili i waena:
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Intermediate N-2 CAS 330786-24-8
Ibrutinib Intermediate N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Na Waiwai Kemika:

Inoa Kimia	3-(4-Phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
Nā huaʻōlelo like	Ibrutinib intermeidate N-2;Ibrutinib Deacryloylpiperidine;Ibrutinib haumia 8;5-(4-Phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine;IBT4A;ʻO Ibrutinib N-Despiperidinyl ka haumia
Helu CAS	330786-24-8
Kūlana Kūʻai	Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā tona
ʻĀpana Molekala	C17H13N5O
Kaumaha Molecular	303.32
Lae hehee	>262℃(Dek.)
ʻO ka mānoanoa	1.380±0.06 g/cm3
Papa Hazard	6.1;ʻawaʻawa
Hui Pūʻulu	III
COA & MSDS	Loaʻa
Ke kumu	Shanghai, Kina
Brand	Kemika Ruifu

Nā kikoʻī:

'ikamu	Nā kikoʻī
Ka nana aku	Keʻokeʻo a hiki i ka pauda Khaki
ʻIkepili	HNMR, LC-MS
Maʻemaʻe / Kaʻina Hanana	>99.0% (HPLC)
Nalo ma ka maloo	<1.00%
Single Max.haumia	<1.00%
Huina paumaele	<1.00%
Nā Metala Kaumaha (e like me Pb)	<20ppm
Kūlana hoʻāʻo	ʻOihana Kūlana
Hoʻohana	Kūwaena o Ibrutinib (CAS: 936563-96-1)

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai.

Pono:

FAQ:

330786-24-8 - Noi:

ʻO 3-(4-Phenoxyphenyl) -1H-pyrazolo [3,4-d] pyrimidin-4-amine (CAS: 330786-24-8) he mea hoʻoheheʻe synthetic pono i ka synthesis o Ibrutinib (CAS: 936563-96-1 ).ʻO Ibrutinib kahi ʻano o Bruton tyrosine kinase (BTK) inhibitor, hiki ke hoʻohana ʻia no ka mālama ʻana i ka maʻi maʻi lymphocytic leukemia (CLL) a me ka lymphoma cell mantle (MCL).No ka B-cell non-Hodgkin's lymphoma ka MCL a me CLL, he paʻakikī ke ho'ōla a maʻalahi hoʻi e hoʻi hou.ʻAʻole loaʻa i ka immunotherapy kemika maʻamau ka huli ʻana, loaʻa pinepine i 3 a 4 mau hopena ʻino.Hiki i nā lymphocytes Ibrutinib a me B ke hoʻopaʻa i ka BTK pono no ka hoʻokumu ʻana, ka ʻokoʻa, a me ka hoʻouna ʻana i ka ʻike, kaohi ʻana i ka hana BTK me ka hiki ʻole ke hoʻihoʻi hou ʻia, a ke keʻakeʻa i ka hoʻonui ʻana o ka cell tumo a ola pono.Hiki ke hoʻopili koke ʻia ʻo Ibrutinib ma hope o ka hoʻokele waha, i ka wā o 1 ~ 2h hiki ke kiʻekiʻe o ke koko, nā hopena ʻino i hoʻokahi a ʻelua paha, no laila, e lilo ʻo Ibrutinib i koho hou no ka mālama ʻana iā CLL a me MCL.